Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Other Non-Current Assets (2016 - 2026)

Insight Molecular Diagnostics' Other Non-Current Assets history spans 7 years, with the latest figure at $607000.0 for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets fell 64.29% to $607000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $607000.0, a 64.29% decrease, with the full-year FY2025 number at $607000.0, down 64.29% from a year prior.
  • Other Non-Current Assets hit $607000.0 in Q4 2025 for Insight Molecular Diagnostics, down from $672000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Assets for IMDX hit a ceiling of $29.7 million in Q4 2021 and a floor of $259000.0 in Q3 2021.
  • Historically, Other Non-Current Assets has averaged $2.5 million across 5 years, with a median of $1.2 million in 2022.
  • Biggest five-year swings in Other Non-Current Assets: skyrocketed 5255.26% in 2021 and later plummeted 98.75% in 2022.
  • Tracing IMDX's Other Non-Current Assets over 5 years: stood at $29.7 million in 2021, then plummeted by 98.75% to $371000.0 in 2022, then surged by 358.22% to $1.7 million in 2023, then changed by 0.0% to $1.7 million in 2024, then plummeted by 64.29% to $607000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for IMDX at $607000.0 in Q4 2025, $672000.0 in Q3 2025, and $1.7 million in Q2 2025.